Your browser doesn't support javascript.
loading
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
McKenney, Anna Sophia; Lau, Allison N; Somasundara, Amritha Varshini Hanasoge; Spitzer, Barbara; Intlekofer, Andrew M; Ahn, Jihae; Shank, Kaitlyn; Rapaport, Franck T; Patel, Minal A; Papalexi, Efthymia; Shih, Alan H; Chiu, April; Freinkman, Elizaveta; Akbay, Esra A; Steadman, Mya; Nagaraja, Raj; Yen, Katharine; Teruya-Feldstein, Julie; Wong, Kwok-Kin; Rampal, Raajit; Vander Heiden, Matthew G; Thompson, Craig B; Levine, Ross L.
Afiliação
  • McKenney AS; Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, New York, USA.
  • Lau AN; Gerstner Sloan Kettering Graduate School of Biomedical Sciences, and.
  • Somasundara AVH; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Spitzer B; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Intlekofer AM; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Ahn J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Shank K; Lymphoma Service.
  • Rapaport FT; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Patel MA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Papalexi E; Center for Hematologic Malignancies.
  • Shih AH; Center for Hematologic Malignancies.
  • Chiu A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Freinkman E; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Akbay EA; Leukemia Service, Department of Medicine, and.
  • Steadman M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Nagaraja R; Whitehead Institute, Cambridge, Massachusetts, USA.
  • Yen K; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Teruya-Feldstein J; Agios Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Wong KK; Agios Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Rampal R; Agios Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Vander Heiden MG; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Thompson CB; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Levine RL; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J Clin Invest ; 128(2): 789-804, 2018 02 01.
Article em En | MEDLINE | ID: mdl-29355841
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / Janus Quinase 2 / Isocitrato Desidrogenase / Transtornos Mieloproliferativos / Antineoplásicos Tipo de estudo: Diagnostic_studies Limite: Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Invest Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / Janus Quinase 2 / Isocitrato Desidrogenase / Transtornos Mieloproliferativos / Antineoplásicos Tipo de estudo: Diagnostic_studies Limite: Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Invest Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos